Vir(US:VIR) ZACKS·2025-05-07 23:20Company Performance - Vir Biotechnology reported a quarterly loss of $0.88 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.83, and compared to a loss of $0.48 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $3.03 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 84.51%, and a sharp decline from year-ago revenues of $56.38 million [2] - Over the last four quarters, Vir Biotechnology has only surpassed consensus EPS estimates once, indicating ongoing challenges in meeting market expectations [2] Stock Performance - Since the beginning of the year, Vir Biotechnology shares have lost approximately 23.3%, significantly underperforming the S&P 500, which declined by 4.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.84 on revenues of $15.97 million, and for the current fiscal year, it is -$3.40 on revenues of $61.56 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Vir Biotechnology belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a relatively strong position within the sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Vir Biotechnology's stock performance [5]